| Study (weights in apixaban-assigned cohorts only) | Minimum body weight | Maximum body weight | Mean body weight | |||
|---|---|---|---|---|---|---|
| (Therapeutic area) | kg | lbs | kg | lbs | kg | lbs |
| ARISTOTLE1 (NVAF) |
29.4 | 64.7 | 204.9 | 450.8 | 83.93 | 184.6 |
| AVERROES1 (NVAF) |
32.7 | 71.9 | 199.5 | 438.9 | 79.5 | 174.9 |
| AMPLIFY2 (VTE) |
28.9 | 63.6 | 210.0 | 462.0 | 84.6 | 186.1 |
| AMPLIFY-EXT2 (VTE) |
42.0 | 92.4 | 192.7 | 423.9 | 85.7 | 188.5 |
| ADVANCE 13 (TKR) |
41.0 | 90.2 | 163.7 | 360.1 | 86.7 | 190.7 |
| ADVANCE 23 (TKR) |
42.0 | 92.4 | 135.0 | 297.0 | 78.7 | 173.1 |
| ADVANCE 33 (THR) |
37.0 | 81.4 | 179.9 | 395.8 | 79.9 | 175.8 |
Please use landscape view or desktop screen to view the content.
Baseline Weight (Mean and Range) in apixaban Trials – ARISTOTLE, AVERROES, AMPLIFY, AMPLIFY-EXT, AND ADVANCE
